Evolus, Inc. (NASDAQ:EOLS - Free Report) - HC Wainwright dropped their FY2025 EPS estimates for shares of Evolus in a report released on Wednesday, March 5th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.23) per share for the year, down from their previous forecast of $0.11. HC Wainwright currently has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Evolus' current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus' FY2026 earnings at $0.49 EPS, FY2027 earnings at $1.16 EPS, FY2028 earnings at $2.35 EPS and FY2029 earnings at $3.81 EPS.
EOLS has been the subject of a number of other research reports. Barclays increased their price target on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.
Read Our Latest Analysis on EOLS
Evolus Price Performance
Evolus stock traded down $0.40 during mid-day trading on Monday, reaching $13.02. 380,433 shares of the company's stock traded hands, compared to its average volume of 592,516. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a 50 day moving average of $13.06 and a two-hundred day moving average of $14.01. The company has a market cap of $827.65 million, a price-to-earnings ratio of -14.38 and a beta of 1.28.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of the company. Creative Planning grew its position in shares of Evolus by 23.7% during the 3rd quarter. Creative Planning now owns 15,451 shares of the company's stock worth $250,000 after buying an additional 2,963 shares in the last quarter. GSA Capital Partners LLP lifted its holdings in Evolus by 335.3% during the third quarter. GSA Capital Partners LLP now owns 120,964 shares of the company's stock worth $1,960,000 after buying an additional 93,176 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in shares of Evolus during the 3rd quarter worth $212,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Evolus in the third quarter valued at about $940,000. Finally, Intech Investment Management LLC bought a new stake in shares of Evolus in the 3rd quarter valued at about $228,000. 90.69% of the stock is currently owned by hedge funds and other institutional investors.
Evolus Company Profile
(
Get Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
